# Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)

> **NCT04543994** · PHASE1,PHASE2 · TERMINATED · sponsor: **The Cleveland Clinic** · enrollment: 7 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Remestemcel-L
- **DRUG:** Remestemcel-L
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04543994
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-10
- **Primary completion:** 2023-11-15
- **Final completion:** 2023-11-15
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** PI left Cleveland Clinic
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04543994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04543994, "Study of Mesenchymal Stem Cells for the Treatment of Medically Refractory Ulcerative Colitis (UC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04543994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*